Major Pathologic Response in Patients Treated for Non–small Cell Carcinoma of the Lung: Is There a Magic Number in the Histologic Sections to Be Evaluated?

Over the last years, great advancements have taken place in the medical approach to lung non–small cell carcinomas. Currently, with the use of biomarkers and diagnostic molecular pathology, tumors that in the past were treated with conventional chemotherapy, radiation therapy, or both, now similar patients afflicted by non–small cell carcinoma may have other alternative treatments. More importantly, because of those advancements in treatment...